Designed multiple ligands: Basic research vs clinical outcomes

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3353-3387

  Costantino, L ^a   Barlocco, D ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti inflammatory compounds; Antibacterials; Antihistamines; Antiparasitic; Cancer treatment; Cardiovascular diseases treatment; Design strategy; Designed multiple ligands; Diabetes treatment; Drug coadministration; Multifactorial pathologies; Multitarget compounds; Neurodegenerative syndromes treatment; Polypharmacology; Psychiatric disorders treatment

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALZHEIMER DISEASE VACCINE; ASENAPINE; BLONANSERIN; DIMEBON; DONEPEZIL; FLUOXETINE; GALANTAMINE; GSK 773812; HALOPERIDOL; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LADOSTIGIL; LURASIDONE; MEMANTINE; MEMOQUIN; NIFEDIPINE; NOOTROPIC AGENT; NP 0361; POMAGLUMETAD METHIONIL; RISPERIDONE; RIVASTIGMINE; SEMAGACESTAT; SEROTONIN ANTAGONIST; TACRINE; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ALZHEIMER DISEASE; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL STUDY; DIABETES MELLITUS; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MOOD DISORDER; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RESEARCH;

EID: 84863751896     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215883     Document Type: Review

References (332)

1. Swinney, D.C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Disc., 2011, 10(7), 507-519.
2. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48(21), 6523-6543.
3. Geldenhuys, W.J.; Youdim, M.B.H.; Carroll, R.T.; Van der Schyf, C.J. The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol., 2011, 94(4), 347-359.
4. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurology, 2010, 9(7), 702-716.
5. Karran, E.M.; Mercken, M.; De Strooper, B. The amyloid cascade hypotheis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Disc., 2011, 10(9), 698-712.
6. Web site of Noscira, a biopharmaceutical company: www.noscira.com (Accessed February 14, 2012).
7. Bembenek, S.D.; Keith, J.M.; Letavic, M.A.; Apodaca, R.; Barbier, A.J.; Dvorak, L.; Aluisio, L.; Miller, K.L.; Lovenberg, T.W.; Carruthers, N.I. Lead identification of acetyilcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorg. Med. Chem., 2008, 16(6), 2968-2973.
8. Potter, L.T.; Ferrendelli, C.A.; Hanchett, H.E.; Hollifield, M.A.; Lorenzi, M.V. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors. Mol. Pharmacol., 1989, 35(5), 652-660.
9. Flynn, D.D.; Mash, D.C. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J Pharmacol. Exp. Ther., 1989, 250(2), 573-581.
10. Mohr, K.; Trankle, C.; Holzgrabe, U. Structure/activity relationships of M2 muscarinic allosteric modulators. Recept. Channels, 2003, 9, 229-240.
11. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51(3), 347-372.
12. de los Rios, C; Egea, J.; Marco-Contelles, J.; Leon, R.; Samadi, A.; Iriepa, I.; Moraleda, I.; Galvez, E.; Garcia, A.G.; Lopez, M.G.; Villaroya, M.; Romero, A. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1, 8-naphtyridine derivatives. J. Med.Chem., 2010, 53(14), 5129-5143.
13. Marco-Contelles, J.; Leon, R.; de los Rios, C; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F.J.; Rodriguez-Franco, M.I.; Lopez, B.; Lopez, M.G.; Garcia, A.G.; do Carmo Carreiras, M.; Villaroya, M. Tacripyrines, the first Tacrine-dihydropyridine hybrids, as multitarget directed ligands for the treatment of Alzheimer's disease. J. Med. Chem., 2009, 52(9), 2724-2732.
14. Spuch, C; Antequera, D.; Fernandez-Bachiller, M. I.; Rodríguez- Franco, M. I.; Carro, E. A. New tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease. Neurotox. Res., 2010, 17(4), 421-431.
15. Fernandez-Bachiller, M. I.; Perez, C; Campillo, N. E.; Paez, J. A.; Gonzalez-Munoz, G. C; Usan, P.; García-Palomero, E.; Lopez, M. G.; Villarroya, M.; García, A. G.; Martínez, A.; Rodríguez- Franco, M. I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem., 2009, 4(5), 828-841.
16. Rodríguez-Franco, M. I.; Fernandez-Bachiller, M. I.; Perez, C; Hernandez-Ledesma, B.; Bartolome, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem., 2006, 49(2), 459-462.
17. Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A; Abe, Y; Kaneko. T.; Kogen, H. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem., 2003, 11(21), 4389-4415.
18. Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y; Kaneko, T.; Kogen, H. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem., 2003, 11(9), 1935-1955.
19. Kenna, M.T.M.; Proctor, G.R.; Young, L.C.; Harvey, A.L. Novel Tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J. Med. Chem., 1997, 40(22), 3516-3523.
20. Hirai, K.; Kato, K.; Nakayama, T.; Hayako, H.; Ishihara, Y; Goto, G; Miyamoto, M. Neurochemical effects of 3-[1(phenylmethyl)-4-piperidinyl]-1(2, 3, 4, 5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats. J. Pharmacol Exp. Ther, 1997, 280(3), 1261-1269.
21. Sterling, J.; Herzig, Y; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Finberg, J.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M.B.; Weinstock, M. Novel dual inhibitors of AChE and MAO derived from hydroxyl aminoindan and phenetylamine as potential treatment for Alzheimer's disease. J. Med. Chem., 2002, 45(24), 5260-5279.
22. Weinreb, O.; Mandel, S.; Bar-Am, O.; Yogev-Falach, M.; Avramovich-Tirosh, Y; Amit, T.; Youdim, M.B.H. Multifunctional neuroprotective derivatives of Rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics, 2009, 6(1), 163-174.
23. Melchiorre, C; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V. Polyamines in drug discovery: from the universal template approach to the multitargeted-directed ligand design strategy. J. Med. Chem., 2010, 53(16), 5906-5914.
24. Cavalli, A.; Bolognesi, M.L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem. Int. Ed., 2007, 46(20), 3689-3692.
25. Bolognesi, M.L.; Cavalli, A.; Melchiorre, C. Memoquin: a multi target-directed ligand a san innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics, 2009, 6(1), 152-162.
26. Bolognesi, M.L.; Cavalli, A.; Bergamini, C; Fato, R.; Lenaz, G.; Rosini, M.; Bartolini, M.; Andrisano, V.; Melchiorre, C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem., 2009, 52(23), 7883-7886.
27. Bongarzone, S.; Ngog, A.I.; Tran, H.; Cavalli, A.; Roberti, M.; Carloni, P.; Legname, G.; Bolognesi, M.L. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2, 5-diamino-1, 4-benzoquinones as novel class of bivalent anti-prion compound. J. Med. Chem., 2010, 53(22), 8197-8201.
28. Bolognesi, M.L.; Bartolini, M.; Tarozzi, A.; Morroni, F.; Lizzi, F.; Milelli, A.; Minarini, A.; Rosini, M.; Hrelia, P.; Andrisano, V.; Melchiorre, C. Multitargeted drug discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg. Med. Chem. Lett., 2011, 21(9), 2655-2658.
29. Bolognesi, M.L.; Chriano, G.P.; Bartolini, M.; Mancini, F.; Bottegoni, G.; Maestri, V.; Czvitkovich, S.; Windisch, M.; Cavalli, A.; Minarini, A.; Rosini, M.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Synthesis of monomeric derivatives to probe Memoquin's bivalent interactions. J. Med. Chem., 2011, 54(24), 8299-8304.
30. Galdeano, C; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M.V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillon, C; Gonzalez-Munoz, G.C.; Rodriguez-Franco, M.I.; Bidon-Chanal, A.; Luque, F.J.; Munoz-Torrero, D. Huprine-Tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J. Med. Chem., 2012, 55(2), 661-669.
31. Munoz Torrero, D.; Pera, M.; Relat, J.; Ratia, M.; Galdeano, C; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M.V. Expanding the multipotent profile of huprine-tacrine heterodimers as disease-modifying anti-Alzheimer agents. Neurodegener. Dis., 2012, 10(1-4), 96-99.
32. Pang, Y.P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminoacridine inhibitors of acetylcholinesterase. J Biol. Chem., 1996, 271(39), 23646-23649.
33. Fu, H.; Li, W.; Luo, J.; Lee, N.T.K.; Li, M.; Tsim, K.W.K.; Pang, Y; Youdim, M.B.H.; Han, Y Promising anti-Alzheimer's dimmer bis(7)-tacrine reduces b-amyloid generation by directly inhibit BACE-1 activity. Biochem. Biophys. Res. Commun., 2008, 366(3), 631-636.
34. Minarini, A.; Milelli, A.; Tumiatti, V; Rosini, M.; Simoni, E.; Bolognesi, M.L.; Andrisano, V; Bartolini, M.; Motori, E.; Angeloni, C; Hrelia, S. Cystamine-tacrine dimer: a new-multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Neuropharmacology, 2012, 62(2), 997-1003.
35. Weinreib, O.; Mandel, S.; Bar-Am, O.; Yogev-Falach, M.; Avramovich-Tirosh, Y; Amit, T.; Youdim, M.B.H. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics, 2009, 6(1), 163-174.
36. Wong, E.H.F.; Tarazi, F.I.; Shahid, M. The effectiveness of multi-targeted agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol. Ther, 2010, 126(2), 173-185.
37. Preskorn, S.H. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide. J. Psychiatr. Pract., 2008, 14(3), 170-175.
38. Preskorn, S.H.; Lacey, R.L. Polypharmacy: when is it rational? J. Psychiatr. Pract., 2007, 13(2), 97-105.
39. Kim, D.H.; Maneen, M.J.; Stahl, S.M. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics, 2009, 6(1), 78-85.
40. Lowe, J.A. Atypical antipsychotics based on the D2/5-HT2 ratio hypothesis. Curr. Med. Chem., 1994, 1(1), 50-60.
41. Wadenberg, M.L.; Wiker, C; Svensson, T.H. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive a2 adrenoceptor blockade: experimental evidence. Int. J. Neuropsychopharmacol., 2007, 10(2), 191-202.
42. Kapur, S.; Seeman, P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry, 2001, 158(3), 360-369.
43. Lieberman, J.A.; Stroup, T.S.; McEvoy J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, CE.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Eng. J. Med., 2006, 353(12), 1209-1223.
44. Jones, P.B.; Barnes, T.R.E.; Davies, L.; Dunn, G.; Lloyd, H.; Hayhurst, K.P.; Murray, R.M.; Markwick, A.; Lewis, S.W. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: cost utility of the last antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch. Gen. Psychiatry, 2006, 63(10), 1079-1087.
45. Frantz, S. Study shows newer schizophrenia treatments no more effective than old. Nat. Rev. Drug Disc, 2005, 4(11), 872-873.
46. Margolis, R.L. The choice of antipsychotics in schizophrenia. Nat. Neurol., 2009, 5(6), 308-310.
47. Dainippon Sumitomo Pharma Web Page: www.ds-pharma.com/rd/new-value/ lonasen.html (Accessed February 14, 2012).
48. Hino, K.; Kai, N.; Sakamoto, M.; Murata, T.; Oka, M.; Matsumoto, J. Novel potential antipsychotics: 4-phenyl-2-(1-piperazinyl)5, 6, 7, 8, 9, 10-hexahydrocycloocta[b]pyridines. In: Abstract of 200 American Chemical Society Meeting, Division of Medicinal Chemistry, n° 11, Washington DC, August 26-30, 1990.
49. Oka, M.; Noda, Y; Ochi, Y; Furukawa, K.; Une, T.; Kurumiya, S.; Hino, K.; Karasawa, T. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther., 1993, 264(1), 158-165.
50. Ishiyama, T.; Tokuda, K.; Ishibashi, T.; Ito, A.; Toma, S.; Ohno, Y Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced imopairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol., 2007, 572(2-3), 160-70.
51. Nemeroff, C.B.; Lieberman, J.A.; Weiden, P.J.; Harvey, P.D.; Newcomer, J.W.; Schatzberg, A.F.; Kilts, CD.; Daniel, D.G. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr, 2005, 10 (11 Suppl 17), 1-20.
52. Tatsumi, M.; Jansen, K.; Blakely, R.D.; Richelson, E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol., 1999, 368, (2-3) 277-283.
53. Howard, H.; Lowe, J.; Seeger, T.; Seymour, P.; Zorn, S.; Maloney, P.; Ewing, F.; Newman, M.; Schmidt, A.; Furman, J.; Robinson, G.; Jackson, E.; Johnson, C.; Morrone, J. 3-benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem., 1996, 39(1), 143-148.
54. Kelder, J.; De Boer, T.H.; De Graaf, J.S.; Weringa, J.H. Tetracyclic neuroleptics structurally related to Mianserin. In: QSAR and strategies in the design of bioactive compounds; Seydel, J.K. Ed.; VCH, Weinheim, 1985, pp. 162-169.
55. Broekkamp, C.L.E.; De Graaf, J.S.; van Delft, A.M.L. Behavioral pharmacology of trans-5-chloro-2-methyl2, 3, 3a, 12b-tetrahydro-1H-dibenz[2, 3:6, 7]oxepino[4, 5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneim. Forsch. Drug Res., 1990, 40(5), 544-549.
56. Shahid, M.; Walker, G.B.; Zorn, S.H.; Wong, E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol., 2009, 23(1), 65-73.
57. Meltzer, H.Y.; Dritselis, A.; Yasothan, U.; Kirkpatrick, P. Asenapine. Nat. Rev. Drug Disc., 2009, 8(11), 843-844.
58. Citrome, L. Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int. J. Clin. Pract., 2009, 63(12), 1762-1784.
59. Rasmussen, K.; Benvenga, M.J.; Bymaster, F.P.; Calligaro, D.O.; Cohen, I.R.; Falcone, J.F.; Hemrick-Luecke, S.K.; Martin, F.M.; Moore, N.A.; Nisenbaum, L.K.; Schaus, J.M.; Sundquist, S.J.; Tupper, D.E.; Wiernicki, T.R.; Nelson, D.L. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethil)-4-methyl- piperazin-1-yl]-2-methyl-4H-3-thia-4, 9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity (that is associated with weight gain) than olanzapine. J. Pharmacol. Exp. Ther., 2005, 315(3), 1265-1277.
60. Garzya, V.; Forbes, I.T.; Gribble, A.D.; Hadley, M.S.; Lightfoot, A.P.; Payne, A.H.; Smith, A.B.; Douglas, S.E.; Cooper, D.G.; Stansfield, I.G.; Meeson, M.; Dodds, E.E.; Jones, D.N.C.; Wood, M.; Reavill, C.; Scorer, C.A.; Worby, A.; Riley, G.; Eddershaw, P.; Ioannou, C.; Donati, D.; Hagan, J.J.; Ratti, E.A. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg. Med. Chem. Lett., 2007, 17(2), 400-405.
61. Synder, E.M.; Murphy, M.R. Schizophrenia therapy: beyond atypical antipsychotics. Nat. Rev. Drug Disc., 2008, 7(6), 471-472.
62. Acadia Pharmaceutical Web page: http://news.acadiapharm.com (Accessed February 14, 2012).
63. Rinaldi-Carmona, M.; Congy, C.; Santucci, V.; Simiand, J.; Gautret, B.; Neliat, G.; Labeeuw, B.; Le Fur, G.; Soubrie, P.; Breliere, J.C. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytriptamine2 receptor antagonist. J. Pharmacol. Exp.Ther., 1992, 262(2), 759-768.
64. von Coburg, Y.; Kottke, T.; Weizel, L.; Ligneau, X.; Stark, H. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg. Med. Chem. Lett., 2009, 19, 538-542.
65. Urban, D.J.; Vargas, G.A.; von Zastrow, M.; Mailman, R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology, 2007, 32(1), 67-77.
66. Banno, K.; Fujioka, T.; Kikuchi, T.; Oshiro, Y.; Hiyama, T.; Nakagawa, K. Studies on 2(1H)-quinolinone derivatives as neuroleptic agents. 1. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives. Chem. Pharm. Bull., 1988, 36(11), 4377-4388.
67. Yasuda, Y.; Kikuchi, T.; Suzuki, S.; Tatsui, M.; Yamada, K.; Hiyama, T. 7-[3-(4-[2, 3-dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci., 1988, 42(20), 1941-1954.
68. Grady, M.A.; Gasperoni, T.L.; Kirkpatrick, P. Aripiprazole. Nat. Rev. Drug Disc., 2003, 2(6), 427-428.
69. Seo, H.J.; Park, E.J.; Kim, M.J.; Kang, S.Y.; Lee, S.H.; Kim, H.J.; Lee, K.N.; Jung, M.E.; Lee, M.W.; Kim, M.S.; Son, E.J.; Park, W.K.; Kim, J.; Lee, J. Design and synthresis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT2A receptor and 5-HT transporter. J. Med. Chem., 2011, 54(18), 6305-6318.
70. Kang, S. Y.; Park, E.-J.; Park, W.-K.; Kim, H. J.; Jeong, D.; Jung, M. E.; Song, K.-S.; Lee, S. H.; Seo, H. J.; Kim, M. J.; Lee, M.; Han, H.-K.; Son, E.-J.; Pae, A. N.; Kim, J.; Lee, J. Arylpiperazine containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant. Bioorg. Med. Chem. Lett., 2010, 20(5), 1705-1711.
71. Kang, S. Y.; Park, E.-J.; Park, W.-K.; Kim, H. J.; Choi, G.; Jung, M. E.; Seo, H. J.; Kim, M. J.; Pae, A. N.; Kim, J.; Lee, J. Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant. Bioorg. Med. Chem., 2010, 18(16), 6156-6169.
72. Kim, J. Y.; Kim, D.; Kang, S. Y.; Park, W.-K.; Kim, H. J.; Jung, M. E.; Son, E.-J.; Pae, A.N.;Kim, J.; Lee, J. Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant. Bioorg. Med. Chem. Lett., 2010, 20(22), 6439-6442.
73. Feenstra, R.W.; de Moes, J.; Hofma, J.J.; Kling, H.; Kuipers, W.; Long, S.K.; Tulp, M.T.M.; van der Heyden, J.A.M.; Kruse, C.G. New 1-aryl-4- (biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A receptor affinities. Bioorg. Med. Chem. Lett., 2001, 11(17), 2345-2349.
74. Lundbeck A/S company Web page: www.lundbeck.com/global (Accessed February 14, 2012).
75. Intracellular Therapies Inc. Web page: www.intracellulartherapies.com (Accessed February 14, 2012).
76. Woolley, M.L.; Carter, H.J.; Gartlon, J.E.; Watson, J.M.; Dawson, L.A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur. J. Pharmacol., 2009, 603(1-3), 147-149.
77. Heinrich, J.N.; Butera, J.A.; Carrick, T.; Kramer, A.; Kowal, D.; Lock, T.; Marquis, K.L.; Pausch, M.H.; Popiolek, M.; Sun, S.C.; Tseng, E.; Uveges, A.J.; Mayer, S.C. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol., 2009, 605(1-3), 53-56.
78. Grant, M.K.; El-Fakahany, E.E. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor. J. Pharmacol. Exp. Ther., 2005, 315(1), 313-9.
79. Lieberman, J.A.; Javitch, J.A.; Moore, H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psichiatry. Am. J. Psychiatry, 2008, 165(8), 931-936.
80. Shekhar, A.; Potter, W.Z.; Lightfoot, J.; Lienemann, J.; Dubé, S.; Mallinckrodt, C.: Bymaster, F.P.; McKinzie, D.L.; Felder, C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry, 2008, 165(8), 1033-1039.
81. Sauerberg, P.; Olesen, P.H.; Nielsen, S.; Treppendahl, S.; Sheardown, M.J.; Honore, T.; Mitch, C.H.; Ward, J.S.; Pike, A.J.; Bymaster, F.P.; Sawyer, B.D.; Shannon, H.E. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1, 2, 5-thiadiazolyl)-1, 2, 5, 6-tetrahydro-1-methylpyridines. J. Med. Chem., 1992, 35(12), 2274-2283.
82. Stanhope, K.J.; Mirza, N.R.; Bickerdike, M.J.; Bright, J.L.; Harrington, N.R.; Hesselink, M.B.; Kennett, G.A.; Lightowler, S.; Sheardown, M.J.; Syed, R.; Upton, R.L.; Wadsworth, G.; Weiss, S.M.; Wyatt, A. The muscarinic receptor agonist xanomeline has an antypsichotic-like profile in rats. J. Pharmacol. Exp. Ther., 2001, 299(2), 782-792.
83. Andersen, M.B.; Fink-Jensen, A.; Peacock, L.; Gerlach, J.; Bymaster, F.; Lundbaek, J.A.; Werge, T. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology, 2003, 28(6), 1168-1175.
84. Mirza, N.R.; Peters, D.; Sparks, R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Reviews, 2003, 9(2), 159-186.
85. Fang, L.; Jumpertz, S.; Zhang, Y.; Appenroth, D.; Fleck, C.; Mohr, K.; Trankle, C.; Decker, M. Hybrid molecules from xanomeline and Tacrine: enhanced Tacrine actions on cholinesterases and muscarinic M1 receptors. J. Med. Chem., 2010, 53(5), 2094-2103.
86. Clinicaltrials.gov (a service of the U.S. National Insitute of Health) Web site: www.clinicaltrials.gov (Accessed February 14, 2012).
87. Maryanoff, B.E.; McComsey, D.F.; Castanzo, M.J.; Setler, P.E.; Gardocki, J.F.; Shank, R.P.; Schneider, C.R. Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J. Med. Chem., 1984, 27(8), 943-946.
88. Maryanoff, B.E.; McComsey, D.F.; Gardocki, J.F.; Shank, R.P.; Costanzo, M.J.; Nortey, S.O.; Schneider, C.R.; Setler, P.E. Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships. J. Med. Chem., 1987, 30(8), 1433-1454.
89. Maryanoff, B.E.; Vaught, J.L.; Shank, R.P.; McComsey, D.F.; Costanzo, M.J.; Nortey, S.O.; Pyrroloisoquinoline antidepressants. 3. A focus on serotonin. J. Med. Chem., 1990, 33(10), 2793-2797.
90. Aluisio, L.; Lord, B.; Barbier, A.; Fraser, I.; Wilson, S.; Boggs, J.; Dvorak, L.; Letavic, M.; et al 2008, In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur. J. Pharmacol., 2008, 587(1-3), 141-146.
91. Carlier, P.R.; Lo, M.M.; Lo, P.C.; Richelson, E.; Tatsumi, M.; Reynolds, I.J.; Sharma, T.A.; Synthesis of a potent wide-spectrum serotonin-, norepinephrine-dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg. Med. Chem. Lett., 1998, 8(5), 487-492.
92. Liang, Y.; Shaw, A.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P.R.; Richelson, E. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S, 2S)-3-(methylamino)-2-(naphtalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J. Pharmacol. Exp. Ther., 2008, 327(2), 573-583.
93. Gopishetty, B.; Hazeldine, S.; Santra, S.; Johnson, M.; Modi, G.; Ali, S.; Zhen, J.; Reith, M.; Dutta, A. Further structure-activity relationship studies on 4-((((3S, 6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl) phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents. J. Med. Chem., 2011, 54(8), 2924-2932.
94. Dutta, A.K.; Ghosh, B.; Biswas, S.; Reith, M.E. D-161, a novel pyran-based triple monoamine transporter bocker: behavioral pharmacological evidence for antidepressant-like action. Eur. J. Pharmacol., 2008, 589(1-3), 73-79.
95. By Van der Zee, P.; Koger, H.S.; Gootjes, J.; Hespe, W. Aryl 1, 4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem., 1980, 15(4), 363-370.
96. Lovell, P.J.; Blaney, F.E.; Goodacre, C.J.; Scott, C.M.; Smith, P.W.; Starr, K.R.; Thewlis, K.M.; Vong, A.K.K.; Ward, S.E.; Watson, J.M. 3, 4-dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(4), 1033-1036.
97. Serafinowska, H.T.; Blaney, F.E.; Lovell, P.J.; Merlo, G.G.; Scott, C.M.; Smith, P.W.; Starr, K.R.; Watson, J.M. Novel 5-HT1A/1B/1D receptors antagonists with potent 5-HT reuptake inhibitory activity. Bioorg. Med. Chem. Lett., 2008, 18(20), 5581-5585.
98. Bromidge, S.M.; Bertani, B.; Borriello, M.; Faedo, S.; Gordon, L.J.; Granci, E.; Hill, M.; Marshall, H.R.; Stasi, L.P.; Zucchelli, V.; Merlo, V.; Vesentini, A.; Watson, J.M.; Zonzini, L. 6-[2-(4-aryl-1-piperazinyl)ethyl]-2H-1, 4-benzoxazin-3(4H)-ones: dual acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(20), 5653-5656.
99. Bromidge, S.M.; Bertani, B.; Borriello, M.; Bozzoli, A.; Faedo, S.; Gianotti, M.; Gordon, L.J.; Hill, M.; Zucchelli, V.; Watson, J.M.; Zonzini, L. 8-[2-(4-aryl-1-piperazinyl)ethyl]-2H-1, 4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors-Part II. Bioorg. Med. Chem. Lett., 2009, 19(8), 2338-2342.
100. Bromidge, S.M.; Arban, R.; Bertani, B.; Borriello, M.; Capelli, A.M.; Di Fabio, R.; Faedo, S.; Gianotti, M.; Gordon, L.J.; Granci, E.; Pasquarello, A.; Spada, S.K.; Worby, A.; Zonzini, L.; Zucchelli, V. 5[2-4-(2-Methyl-5-quinolinyl) -1-piperazinyl]ethyl]-2(1H)-quinolinines and 3, 4-dihydro-2(1H)-quinolinines: dual acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3. Bioorg. Med. Chem. Lett., 2010, 20(23), 7092-7096.
101. Bromidge, S.M.; Arban, R.; Bertani, B.; Bison, S.; Borriello, M.; Cavanni, P.; Dal Forno, G.; Di Fabio, R.; Donati, D.; Fontana, S.; Gianotti, S.; Gordon, L.J.; Granci, E.; Leslie, C.P.; Moccia, L.; Pasquarello, A.; Sartori, I.; Sava, A.; Watson, J.M.; Worby, A.; Zonzini, L.; Zucchelli, V. Design and synthesis of novel tryciclic benzoxazines as potent 5-HT1A/B/D receptor antagonists leading to the discovery of 6[2-[4-(2-methyl-5-quinolonyl)-1- piperazinyl]ethyl]-4H-imidazo-[5, 1-c][1, 4]benzoxazine-3-carboxamide (GSK588045). J. Med. Chem., 2010, 53(15), 5827-5843.
102. Leslie, C.P.; Biagetti, M.; Bison, S.; Bromidge, S.M.; Di Fabio, R.; Donati, D.; Falchi, A.; Garnier, M.J.; Jaxa-Chamiec, A.; Manchee, G.; Merlo, G.; Pizzi, D.A.; Stasi, L.P.; Tibasco, J.; Vong, A.; Ward, S.E.; Zonzini, L. Discovery of 1-(3-[2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl)-2- imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT1A/B/D receptor antagonist. J. Med. Chem., 2010, 53(23), 8228-8240.
103. Ward, S.E.; Eddershaw, P.J.; Scott, C.M.; Gordon, L.J.; Lovell, P.J.; Moore, S.H.; Smith, P.W.; Starr, K.R.; Thewlis, K.M.; Watson, J.M. Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists. J. Med. Chem., 2008, 51(10), 2887-2890.
104. Micheli, F.; Cavanni, P.; Arban, R.; Benedetti, R.; Bertani, B.; Bettati, M.M; Bettelini, L.; Bonanomi, G.; Braggio, S.; Checchia, A.; Davalli, S.; Di Fabio, R.; Fazzolari, E.; Fontana, S.; Marchioro, C.; Minick, D.; Negri, M.; Oliosi, B.; Read, K.D.; Sartori, I.; Tedesco, G.; Tarsi, L.; Terreni, S.; Visentini, F.; Zocchi, A.; Zonzini, L. 1-(aryl)-6-[alkoxyalkyl]-3-azabyciclo[3. 1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J. Med. Chem., 2010, 53(6), 2534-2551.
105. Micheli, F.; Cavanni, P.; Andreotti, D.; Arban, R.; Benedetti, R.; Bertani, B.; Bettati, M.; Bettelini, L.; Bonanomi, G.; Braggio, S.; Carletti, R.; Checchia, A.; Corsi, M.; Fazzolari, E.; Fontana, S.; Marchioro, C.; Merlo-Pich, E.; Negri, M.; Oliosi, B.; Ratti, E.; Read, K.D.; Roscic, M.; Sartori, I.; Spada, S.; Tedesco, G.; Tarsi, L.; Terreni, S.; Visentini, F.; Zocchi, A.; Zonzini, L.; Di Fabio, R. 6-(3, 4-dichlorophenyl)-1-[(methyloxy) methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J. Med. Chem., 2010, 53(13), 4989-5001.
106. Andersen, B.B.; Ruhland, T.; Jorgensen, M.; Smith, G.; Frederiksen, K.; Jensen, K.G.; Zhong, H.; Nielsen, S.M.; Hogg, S.; Mork, A.; Stensbol, T.B. Discovery of 1-[2(2, 4-dimethylphenylsulphanyl)phenyl]piperazine (LU AA21004): a novel multimodal compound for the treatment of mayor depressive disorder. J. Med. Chem., 2011, 54(9), 3206-3221.
107. Cashman, J.R.; Voelker, T.; Zhang, H.T.; O'Donnell, J.M. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J. Med. Chem., 2009, 52(6), 1530-1539.
108. Cashman, J.R.; Ghirmai, S. Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg. Med. Chem., 2009, 17(19), 6890-6897.
109. Castiglioni, E.; Di Fabio, R.; Togninelli, A.; Brough, S.; Brown, F.; Dal Cin, M.; Gianotti, M.; Marchioro, C.; Merlo, G.; Spinosa, R.; Wigglesworth, M.J.; Botta, M. Towards the discovery of new hypnotic agents: synthesis and preliminary pharmacological evaluation of a novel class of dibenzo[a, d]cycloheptene derivatives. ChemMedChem, 2010, 5(11), 1843-1846.
110. Gianotti, M.; Botta, M.; Brough, S.; Carletti, R.; Castiglioni, E.; Corti, C.; Dal Cin, M.; Delle Fratte, S.; Korajac, D.; Lovric, M.; Merlo, G.; Mesic, M.; Pavone, F.; Piccoli, L.; Rast, S.; Roscic, M.; Sava, A.; Smehil, M.; Stasi, L.; Togninelli, A.; Wigglesworth, M.J. Novel spirotetracyclic zwitterionic dual H1/5-HT2A receptor antagonists for the treatment of sleep disorders. J. Med. Chem., 2010, 53(21), 7778-7795.
111. Altenbach, R.J.; Black, L.A.; Strakhova, M.I.; Manelli, A.M.; Carr, T.L.; Marsh, K.C.; Wetter, J.M.; Wensink, E.J.; Hsieh, G.C.; Honore, P.; Runyan Garrison, T.; Brioni, J.D.; Cowart, M.D. Diarylamines with dual inhibition of the histamine H3 receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy) naphtalen-1-ol in pain. J. Med. Chem., 2010, 53(21), 7869-7873.
112. Trstenjak, U.; Kikelj, D. Multitarget cardiovascular drugs. Curr. Med. Chem., 2011, 18(17), 2531-2542.
113. Robl, J.; Sieber-McMaster, E.; Asaad, M.M.; Bird, J.E.; Delaney, N.G.; Barrish, J.C.; Neubeck, R.; Natarajan, S.; Cohen, M.; Rovnyak, G.C.; Huber, G.; Murugesan, N.; Girotra, R.; Cheung, H.S.; Waldron, T.; Petrillo, E.W. Mercaptoacyldipeptides as dual inhibitors of angiotensin converting enzyme and neutral peptidase. Preliminary structure-activity studies. Bioorg. Med. Chem. Lett., 1994, 4(15), 1783-1789.
114. Robl, J.A.; Sun, C.Q.; Stevenson, J.; Ryono, D.E.; Simpkins, L.M.; Cimarusti, M.P.; Dejneka, T.; Slusarchuk, W.A.; Chao, S.; Stratton, L.; Misra, R.N.; Bednarz, M.S.; Asaad, M.M.; Cheung, H.S.; Abboa-Offei, B.E.; Smith, P.L.; Mathers, P.D.; Fox, M.; Schaeffer, T.R.; Seymour, A.A.; Trippodo, N.C. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem., 1997, 40(11), 1570-1577.
115. Cicardi, M.; Zingale, L.C.; Bergamaschini, L.; Agostoni, A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch. Intern. Med., 2004, 164(8), 910-913.
116. Fryer, R.M.; Segreti, J.; Banfor, P.N.; Widomski, D.L.; Backers, B.J.; Lin, C.W.; Ballaron, S.J.; Cox, B.F.; Trevillyan, J.M.; Reinhart, G.A.; von Geldern, T. W. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br. J. Pharmacol., 2008, 153(5), 947-955.
117. Fink, C.A.; Moskal, M.; Firooznia, F.; Hoyer, D.; Symonsbergen, D.; Wei, D.; Qiao, Y.; Savage, P.; Beil, M.E.; Trapani, A.J.; Jeng, A.Y. Design and synthesis of potent thiol-based inhibitors of endothelin-converting enzyme-1. Bioorg. Med. Chem. Lett., 2000, 10(17), 2037-1039.
118. Firooznia, F.; Gude, C.; Chan, K.; Tan, J.; Fink, C.A.; Savage, P.; Beil, M.E.; Bruseo, C.W.; Trapani, A.J.; Jeng, A.Y. Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1. Bioorg. Med. Chem. Lett., 2002, 12(21), 3059-3062.
119. Battistini, B.; Daull, P.; Jeng, A.J. CGS35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc. Drug Rev., 2005, 23(4), 317-330.
120. Daull, P.; Lepage, R.; Benrezzak, O.; Cayer, J.; Beaudoin, M.; Belleville, K.; Blouin, A.; Sirois, P.; Nantel, F.; Jeng, A.Y.; Battistini, B. The first preclinical pharmacotoxicological safety assessment of GGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. Drug Chem. Toxicol., 2006, 29(2), 183-202.
121. Gupta, A.K. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension, 2010, 55, 399-407.
122. Bakris, G.L.; Sarafidis, P.A.; Weir, M.R.; Dahlof, B.; Pitt, B.; Jamerson, K.; Velazquez, E.J.; Staikos-Byrne, L.; Kelly, R.Y.; Shi, V.; Chiang, Y.T.; Weber, M.A. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, 2010, 375(9721), 1173-1181.
123. Wald, N.J.; Law, M.R. A strategy to reduce cardiovascular disease by more than 80%. British Med. J., 2003, 326, 1419. Doi: 10.1136/bmj.326.7404.1419
124. Volpe, M.; Chin, D.; Paneni, F. The challenge of polypharmacy in cardiovascular medicine. Fundam. Clin. Pharmacol., 2010, 9-17.
125. Garcia-Donaire, J.A.; Ruilope, L.M. Multiple action fixed combination. Present or future? Fundam. Clin. Pharmacol., 2010, 24(1), 37-42.
126. Muntner, P.; Mann, D.; Wildman, R.P.; Shimbo, D.; Fuster, V.; Woodward, M. Projected impact of polypill use among US adults: medication use, cardiovascular risk reduction, and side effects. Am. Heart J., 2011, 161(4), 719-725.
127. www.trialsresultscenter.org/DR3-polypillclinicaltrials.htm (Accessed February 14, 2012).
128. Pill Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill ("Polypill") in people with raised cardiovascular risk. PLosOne, 2011, 6, e19857.
129. Paulis, L.; Unger, T. Novel therapeutic targets for hypertension. Nat. Rev. Cardiology, 2010, 7(8), 431-441.
130. Kuhn, B.M. "Polypill" could slash diabetes risks. J. Am. Med. Assoc., 2006, 296(4), 377-380.
131. Gu, J.; Noe, A.; Chandra, P.; Al-Fayoumi, S.; Ligueros-Saylan, M.; Sarangapani, R.; Maahs, S.; Ksander, G.; Rigel, D.F.; Jeng, A.Y.; Lin, T.H.; Zheng, W.; Dole, W. P. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi). J. Clin. Pharmacol., 2010, 50(4), 401-414.
132. Ruilope, L.M.; Dukat, A.; Bohm, M.; Lacourciere, Y.; Gong, J.; Lefkowitz, M.P. Blood-pressure reduction with LCZ-696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet, 2010, 375(9722), 1255-1266.
133. Kobalava, Z.; Paulikova, E.; Averkov, O.; Moiseev, V.; Albrecht, D.; Feng, A.; Chandra, P.; Jordaan, P.J. First experience with concomitant AT1 and neprilysin (NEP 24.11) inhibition with LCZ696 in patients with chronic heart failure. Circulation, 2010, 122, A19378.
134. Murugesan, N.; Tellew, J.E.; Gu, Z.; Kunst, B.L.; Fadnis, L.; Cornelius, L.A.; Baska, R.A.F.; Yang, Y; Beer, S.M.; Monshizadegan, H.; Dickinson, K.E.; Panchal, B.; Valentine, M.T.; Chong, S.; Morrison, R.A.; Carlson, K.E.; Powell, J.R.; Moreland, S.; Barrish, J.C.; Kowala, M.C.; Macor, J.E.; Discovery of N-isoxazolyl biphenylsulfonamides as potent dial Angiotensin II and endothelin A receptor antagonists. J. Med. Chem., 2002, 45(18), 3829-3835.
135. Murugesan, N.; Gu, Z.; Fadnis, L.; Tellew, J.E.; Baska, R.A.F.; Yang, Y; Beyer, S.M.; Monshizadegan, H.; Dickinson, K.E.; Valentine, M.T.; Humpreys, W.G.; Lan, S.J.; Ewing, W.R; Carlson, K.E.; Kowala, M.C.; Zahler, R; Macor, J.E. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J. Med. Chem., 2005, 48(1), 171-179
136. Tellew, J.E., Baska, RA.; Beyer, S.M.; Carlson, K.E.; Cornelus, L.A.; Fadnis, L.; Gu, Z.; Kunst, B.L.; Kowala, M.C.; Monshizadegan, H.; Murugesan, N.; Ryan, CS.; Valentine, M.T.; Yang, Y; Macor, J.E. Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 2003, 13(6), 1093-1096.
137. Garcia, G.; Rodriguez-Puyol, M.; Alajarin, R; Serrano, I.; Sanchez-Alonso, P.; Griera, M.; Vaquero, J.J.; Rodriguez-Puyol, D.; Alvarez-Builla, J.; Diez-Marques, M.L. Lorsartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage. J. Med. Chem., 2009, 52(22), 7220-7227.
138. Iwai, M.; Chen, R; Imura, Y; Horiuchi, M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am. J. Hypertens., 2007, 20(5), 579-586.
139. Mizuno, C.S.; Chittiboyina, A.G.; Patny, A.; Kurtz, T.W.; Pershadsingh, H.A.; Speth, R.C.; Karamyan, V.T.; Avery, M.A. Design, synthesis, and docking studies of telmisartan analogs for the treatment of metabolic syndrome. Med. Chem. Res., 2009, 18(8), 611-628.
140. Lim, S.; Despres, J.P.; Koh, K.K. Prevention of Atherosclerosis in overweight/obese patients In need to novel multi-targeted approaches. Circ. J., 2011, 75(5), 1019-1027.
141. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-substituted benzyl)thiazolidine-2, 4-diones as structurally new antihyperglycemic agents. Bioorg. Med. Chem. Lett., 1999, 9(4), 533-538.
142. Chang, F.; Jaber, L.A.; Berlie, H.D.; O'Connell, M.B. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother., 2007, 41(6), 973-983.
143. Chipscreen Biosciences Ltd. Web page: www.chipscreen.com/en/products-1. asp?id=38 (Accessed February 14, 2012).
144. Willson, T.M.; Brown, P.J.; Sternbach, D.D.; Henke, B.R The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 2000, 43(4), 527-550.
145. Benardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Boehringer, M.; Grether, U.; Hilpert, H.; Kuhn, B.; Marki, H.P; Meyer, M.; Puntener, K.; Raab, S.; Ruf, A.; Schlatter, D.; Mohr, P. Aleglitazar, a new, potent, and balanced dual PPARa/y agonist for the treatment of type II diabetes. Bioorg. Med. Chem. Lett., 2009, 19(9), 2468-2473.
146. Hoffman-La Roche Ltd. Web site: www.roche.com (Accessed February 14, 2012).
147. Sanwald-Ducray, P.; D'ardhuy, X.L.; Jamois, C; Banken, L. Pharmacokinetics, pharmacodynamics, and tolerability of Aleglitazar in patients with Type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin. Pharmacol. Ther, 2010, 88(2) 197-203.
148. Henry, RR; Lincoff, A.M.; Mudaliar, S.; Rabbia, M.; Chognot, C; Herz, M. Effect of dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a Phase 2, randomised, dose-ranging study. Lancet, 2009, 374(9684), 126-135.
149. Artis, D.R; Lin, J.J.; Zhang, C; Wang, W.; Mehra, U.; Perreault, M.; Erbe, D.; Krupka, H.I.; England, B.P.; Arnold, J.; Plotnikov, A.N.; Marimuthu, A.; Nguyen, H.; Will, S.; Signaevsky, M.; Kral, J.; Cantwell, J.; Settachatgull, C; Yan, D.S.; Fong, D.; Oh, A.; Shi, S.; Womack, P.; Powell, B.; Habets, G.; West, B.L.; Zhang, K.Y.J.; Milburn, M.V; Vlasuk, G.P.; Hirth, K.P.; Nolop, K.; Bollag, G.; Ibrahim, P.N.; Tobin, J.F. Scaffold-based discovery of Indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. National Acad. Sci. U.S.A., 2009, 106(1), 262-267.
150. Choi, J.H.; Banks, A.S.; Estall, J.L.; Kajimura, S.; Bostrom, P.; Laznik, D.; Ruas, J.L.; Chalmers, M.J.; Kamenecka, T.M.; Bluher, M.; Griffin, P.R.; Spiegelman, B.M. Anti-diabetic drugs inhibit obesity-linked phosphorilation of PPARyby Cdk5. Nature, 2010, 466(7305), 451-456.
151. Choi, J.H.; Banks, A.S.; Kamenecka, T.M.; Busby, S.A.; Chalmers, M.J.; Kumar, N.; Kuruvilla, D.S.; Shin, Y; He, Y; Bruning, J.B.; Marciano, D.P.; Cameron, M.D.; Laznik, D.; Jurczak, M.J.; Schurer, S.C.; Vidovic, D.; Shulman, G.I.; Spiegelman, B.M.; Griffin, P.R Antidiabetic actions of a non-agonist PPARy ligand blocking Cdk5-mediated phosphorylation. Nature, 2011, 477(7365), 477-483.
152. Kilgore, K.S.; Billin, A.N. PPARbeta/delta ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs, 2008, 9(5), 463-469.
153. Guha, M.; Deng, M.; Malecha, J.; Kabakibi, A.; Oshiro, G.; Rao, T. KD3010, a PPARß/5 selective small molecule agonist, improves hyperglycemia and insulin resistance while alleviating rosiglitazone-induced side effects in murine models. Circulation, 2006, 114, II-843.
154. Perez-Fernandez, R; Fresno, N.; Macias-Gonzalez, M.; Elguero, J.; Decara, J.; Giron, R; Rodriguez-Alvarez, A.; Martin, M.I.; Rodriguez de Fonseca, F.; Goya, P. Discovery of potent dual PPARa agonist/CB1 ligand. ACS Med. Chem. Lett., 2011, 2(11), 793-797.
155. Ye, Y.L.; Zhou, Z.; Zou, HJ.; Shen, Y; Xu, T.F.; Tang, J.; Yin, H.Z.; Chen, M.; Leng, Y; Shen, J.H. Discovery of novel dual functional agent as PPARg agonist and 11ß-HSD1 inhibitor for the treatment of diabetes. Bioorg. Med. Chem., 2009, 17(15), 5722-5732.
156. Welch, D.R; Tomasovic, S.P. The implication of tumor progression on clinical oncology. Clin. Exp. Matast., 1985, 3(3), 151-188.
157. Adams, J.M.; Strasser, A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res., 2008, 68(11), 4018-4021.
158. Shackleton, M.; Quintana, E.; Fearon, E.R; Morrison, S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 2009, 138(5), 822-829.
159. Kamb, A.; Wee, S.; Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Disc, 2007, 6(2), 115-120.
160. Fedi, P.; Aaronson, S.A. Signal transduction through tyrosine kinase growth factor receptors, In: Signaling networks and cell cycle control: the molecular basis of cancer and other diseases; Gutkind, J.S. Ed.; Humana Press inc., Totowa, New Yersey, 2000, pp. 17-38.
161. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Mark Floyd, M.; Hunt, J.P.; Lockhart, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotech., 2008, 26(1), 127-132.
162. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G.K.; Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem., 2008, 51(24), 7898-7914.
163. Posy, S.L.; Hermsmeier, M.A.; Vaccaro, W.; Ott, K.H.; Todderud, G.; Lippy, J.S.; Trainor, G.L.; Loughney, D.A.; Johnson, S.R Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem., 2011, 54(1), 54-66.
164. Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol., 2009, 5(9), 616-625.
165. Conradt, L.; Godl, K.; Schaab, C; Tebbe, A.; Eser, S.; Diersch, S.; Michalski, C.V.; Kleeff, J.; Schnieke, A.; Schmid, RM.; Saur, D.; Schneider, G. Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2011, 13(11), 1026-1034.
166. Dancey, J.; Sausville, E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Disc, 2003, 2(4), 296-313.
167. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9(1), 28-39.
168. Jain, R.K.; Duda, D.G.; Willett, C.G.; Sahani, D.V; Zhu, A.X.; Loeffler, J.S.; Batchelor, T.T.; Sorensen, A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol., 2009, 6(6), 327-338.
169. Weis, S.M.; Cheresh, D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 2011, 17(11), 1359-1370.
170. Bergers, G.; Hanahan, D. Modes of resistence to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8(8), 592-603.
171. Jain, R.K.; Duda, D.G.; Willett, C.G.; Sahani, D.V; Zhu, A.X.; Loeffler, J.S.; Batchelor, T.T.; Sorensen, A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol., 2009, 6(6), 327-338.
172. English, B.C.; Price, D.K.; Figg, W.D. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. Cancer Biol. Ther., 2009, 8(13), 1212-1213.
173. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 2009, 15(3), 220-231.
174. Ebos, J.M.L.; Lee, C.R.; Cruz-Monoz, W.; Bjarnason, G.A.; Christensen, J.G.; Kerbel, RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 2009, 15(3), 232-239.
175. Taeger, J.; Moser, C; Hellerbrand, C; Mycielska, M.E.; Glockzn, G.; Schlitt, HJ.; Geissler, E.K.; Stoeltzing, O.; Lang, S.A. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther, 2011, 10(11), 2157-2167.
176. Bertolini, F.; Marighetti, P.; Martin-Padura, I.; Mancuso, P.; Hu-Lowe, D.D.; Shaked, Y.; D'Onofrio, A. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Disc. Today, 2011, 16(23-24), 1052-1060.
177. Allen, J.; Collingwood, S.P.; Ratcliffe, A.J. Kinase inhibitors from early research to clinic. Highlights of the society for medicines tresearch symposium, held on June 24, 2010, at AstraZeneca, Alderly Park Conference Centre, Alderly Park, Macclesfield, UK. Drugs Fut. 2011, 36(3), 249-263.
178. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem., 1998, 41(14), 2588-2603.
179. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, P.; Hirth, P.; Yeh, B.K.; Hubbard, S.R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 1997, 276(5314), 955-960.
180. Laird, A.D.; Vajcoczy, P.; Shawver, L.K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S.R.; Blake, R.A.; Fong, A.T.; Strawn, L.M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K.P.; McMahon, G.; Cherrington, J.M. SU6668 is a potent antiangiogenic and antitumor agent that induces a regression of established tumors. Cancer Res., 2000, 60(15), 4152-4160.
181. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L.K.; McMahon, G.; Tang, C. Design, synthesis and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem., 1999, 42(25), 5120-5130.
182. Sun, L.; Liangm, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J.Y.; Chu, J.Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T.C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem., 2003, 46(7), 1116-1119.
183. Hennequin, L.F.; Thomas, A.P.; Johnstone, C.; Stokes, E.S.E.; Ple, P.A.; Lohmann, J.J.M.; Ogilvie, D.J.; Dukes, M.; Wedge, S.R.; Curwen, J.O.; Kendrew, J.; Lambert van der Brempt, C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 1999, 42(26), 5369-5389.
184. Hennequin, L.F.; Stokes, E.S.E.; Thomas, A.P.; Johnstone, C.; Ple, P.A.; Ogilvie, D.J.; Dues, M.; Wedge, S.R.; Kendrew, J.; Curwen, J.O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 2002, 45(2), 1300-1312.
185. Harris, P.A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R.M.; DavisWard, R.G.; Epperly, A.H.; Hinkle, K.W.; Hunter, R.N.; Johnson, J.H.; Knick, V.B.; Laudeman, C.P.; Luttrell, D.K.; Mook, R.A., Nolte, R.T.; Rudolph, S.K.; Szewczyk, J.R.; Truesdale, A.T.; Veal, J.M.; Wang, L.; Stafford, J.A. Discovery of 5-[[4-[(2, 3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2- methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem., 2008, 51(15), 4632-4640.
186. Bukovshi, R.M.; Yasothan, U.; Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Disc., 2010, 9(1), 17-18.
187. Kania, R.S. Structure-based design and characterization of Axitinib. In: Kinase Inhibitor Drugs; Li, R.; Stafford, J.A., Eds.; Wiley, Hoboken, New Ye rse y, 2009, pp. 167-201.
188. Gerald, J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem., 2009, 52(14), 4466-4480.
189. Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.; Jansen, J. M.; Wernette-Hammond, M. E.; Harris, A. L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors. J. Med. Chem., 2009, 52(2), 278-292.
190. Bhide, R. S.; Cai, Z.-W.; Zhang, Y.-Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.; Barrish, J. C.; Kim, S.-H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jayaseelan, R., Sr.; Kukral, D.; Hunt, J.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1, 2, 4]triazin-6-yloxy)-propanol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem., 2006, 49(7), 2143-2146.
191. Borzilleri, R.M.; Cai, Z.; Ellis, C.; Fargnoli, J.; Fura, A.; Gerhardt, T.; Goyal, B.; Hunt, J.T.; Mortillo, S.; Qian, L.; Tokarski, J.; Vyas, V., Wautlet, B.; Zheng, X., Bhide, R.S. Synthesis and SAR of 4-(3- hydroxyphenylamino)pyrrolo[2, 1-f][1, 2, 4]triazine based VEGFR-2 kinase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(5), 1429-1433.
192. Borzilleri, R.M.; Zheng, X.; Qian, L.; Ellis, C.; Cai, Z.W.; Wautlet, B.S.; Mortillo, S.; Sr, R.J.; Kukral, D.W.; Fura, A.; Kamath, A.; Vyas, V.; Tokarski, J.S.; Barrish, J.C.; Hunt, J.T.; Lombardo, L.J.; Fargnoli, J.; Bhide, R. Design, synthesis, and evaluation of orally active 4-(2, 4-difluoro-5- (methoxycarbamoyl)phenylamino)pyrrolo[2, 1-f]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J. Med. Chem., 2005, 48(12), 3991-4008.
193. Hunt, J.T.; Mitt, T.; Borzilleri, R.; Gullo-Brown, J.; Fargnoli, J.; Fink, B.; Han, W.C.; Mortillo, S.; Vite, G.; Wautlet, B.; Wong, T.; Yu, C.; Zheng, X.; Bhide, R. Discovery of the pyrrolo[2, 1-f][1, 2, 4]triazine nucleus as a new kinase inhibitor template. J. Med. Chem., 2004, 47(16), 4054-4059.
194. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L. K.; McMahon, G.; Tang, Cho. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)-methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem., 1999, 42(25), 5120-5130.
195. Huang, W.-S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(Imidazo[1, 2-b]pyridazin-3-yl)-ethynyl]-4-methyl-N-[4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl) phenyl]benzamide (AP24534), a potent, orally active pan-inhibitor of Breakpoint Cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem., 2010, 53(12), 4701-4719.
196. Funahashi, Y.; Tsuruoka, A.; Matsukura, M.; Haneda, T.; Fukuda, Y.; Kamata, J.; Takahashi, K.; Matsushima, T.; Miyazaki, K.; Nomoto, K.; Watanabe, T.; Obaishi, H.; Yamaguchi, A.; Suzuki, S.; Nakamura, K.; Mimura, F.; Yamamoto, Y.; Matsui, J.; Matsui, K.; Yoshiba, T.; Suzuki, Y.; Arimoto, I. Nitrogenous aromatic ring compounds. WO2002032872, 2002.
197. Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Wakabayashi, T.; Uenaka, T.; Asada, M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer, 2008, 122(3), 664-671.
198. Michaelides, M.; Albert, D.H. Road to ABT-869: a multitargeted receptor tyrosine kinase inhibitor. In: Kinase Inhibitor Drugs; Li, R.; Stafford, J.A., Eds.; Wiley Hoboken, New Yersey, 2009, pp. 79-112.
199. Dai, Y.; Guo, X.; Frey, R.R.; Ji, Z.; Curtin, M.L.; Ahmed, A.A.; Albert, D.H.; Arnold, L.; Arries, S.S.; Barlozzari, T.; Bauch, J.L.; Bouska, J.J.; Bousquet, P.F.; Cunha, G.A.; Glaser, K.B.; Guo, J.; Li, J.; Marcotte, P.A.; Marsh, K.C.; Moskey, M.D.; Pease, L.J.; Stewart, K.D.; Stoll, V.S.; Tapang, P.; Wishar, N.; Davidsen, S.K.; Michaelides, M.R.; Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem., 2005, 48(19), 6066-6083.
200. Tasker, A.S.; Patel, V.F. Discovery of motesanib. In: Kinase Inhibitor Drugs; Li, R.; Stafford, J.A., Eds.; Wiley, Hoboken, New Yersey, 2009, pp. 113-130.
201. Dominguez, C.; Smith, L.; Huang, Q.; Yuan, C.; Ouyang, X.; Cai, L.; Chen, P.; Kim, J.; Harvey, T.; Syed, R.; Kim, T.S.; Tasker, A.; Wang, L.; Zhang, M.; Coxon, A.; Bready, J.; Starnes, C.; Chen, D.; Gan, Y.; Neervannan, S.; Kumar, G.; Polverino, A.; Kendall, R. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Bioorg. Med. Chem. Lett., 2007, 7(21), 6003-6008.
202. Gingrich, D.E.; Reddy, D.R.; Iqbal, M.A.; Singh, J.; Aimone, L.D.; Angeles, T.S.; Albom, M.; Yang, S.; Meyer, S.; Ator, M.; Robinson, C.; Ruggeri, B.A.; Dionne, C.A.; Vaught, J.L.; Mallamo, J.P.; Hudkins, R.L. A new class of potent VEGF receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alcoxymethyl-12-(3-hydroxypropyl)indeno[2, 1-a]pyrrolo[3, 4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem., 2003, 46(25), 5375-5388.
203. Hudkins, R.L.; Becknell, N.C.; Zulli, A.L.; Underiner, T.L.; Angeles, T.S.; Aimone, L.D.; Albom, M.S.; Chang, H.; Micnyoczki, S.J.; Hunter, K.; Jones-Bolin, S.; Zhao, H.; Bacon, E.R.; Mallamo, J.P.; Ator, M.A.; Ruggeri, B.A. Synthesis and biological profile of the pan-vascular Endothelial Growth Factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12, 13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5, 4-a]pyrrolo[3, 4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent. J. Med. Chem., 2012, 55(2), 903-913.
204. Davies, R.J.; Pierce, A.C.; Forster, C.; Grey, R.; Xu, J.; Arnost, M.; Choquette, D.; Galullo, V.; Tian, S.; Henkel, G.; Chen, G.; Heidary, D.K.; Ma, J.; Stuver-Moody, C.; Namchuk, M. Design, synthesis and evaluation of a novel dual Fms-like tyrosine kinase 3/Stem Cell Factor (FLT-3/c-Kit) inhibitor for the treatment of acute myelogenous leukemia. J. Med. Chem., 2011, 54(20), 7184-7192.
205. Heidary, D.K.; Huang, G.; Boucher, D.; Ma, J.; Forster, C.; Grey, R.; Xu, J.; Arnost, M.; Choquette, D.; Chen, G.; Zhou, J.H.; Yao, Y.M.; Ball, E.D.; Namchuk, M.; Davies, R.J.; Henkel, G. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J. Med. Chem., 2012, 55(2), 725-734.
206. Lackey, K.E. Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr. Top. Med. Chem., 2006, 6(5), 435-460.
207. Moy, B.; Kirkpatrick, P.; Kar, S.; Goss, P. Lapatinib. Nat. Rev. Drug Disc., 2007, 6(6), 431-432.
208. Rusnak, D.; Gilmer, T.M. The discovery of Lapatinib (GW572016). Mol. Cancer Ther., 2011, 11, 2019.
209. Zhang, Y.M.; Cockerill, S.; Guntrip, S.B.; Rusnak, D.; Smith, K.; Vanderwall, D.; Wood, E.; Lackey, K. Synthesis and SAR of potent EGFR/erbB2 dual inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(1), 111-114.
210. Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiyama, K. Design and synthesis of novel Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) dual inhibitors bearing a pyrrolo[3, 2-d]pyrimidine scaffold. J. Med. Chem., 2011, 54(23), 8030-8050.
211. Li, Y.; Tan, C.; Gao, C.; Zhang, C.; Luan, X.; Chen, X.; Liu, H.; Chen, Y.; Jiang, Y. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg. Med. Chem., 2011, 19(13), 4529-4535.
212. Ma, X.; Wang, R.; Tan, C.Y.; Jiang, Y.; Lu, T.; Rao, H.B.; Li, X.Y.; Go, M.L.; Low, B.C.; Chen, Y.Z. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines Mol. Pharm., 2010, 7(5), 1545-1560.
213. OSI Pharmaceuticals Web page: www.osip.com/OSI-906 (Accessed February 14, 2012).
214. Mulvihill, M.J.; Cooke, A.; Rosenfeld-Franklin, M.; Buck, E.; Foreman, K.; Landfair, D.; O'Connor, M.; Pirritt, C.; Sun, Y.; Yao, Y.; Arnold, L.D.; Gibson, N.W.; Ji, Q.S. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor. Fut. Med. Chem., 2009, 1(6), 1153-1171.
215. Mulvihill, M.J.; Ji, Q.S.; Werner, D.; Beck, P.; Cesario, C.; Cooke, A.; Cox, M.; Crew, A.; Dong, H.; Feng, L.; Foreman, K.W.; Mak, G.; Nigro, A.; O'Connor, M.; Saroglou, L.; Stolz, K.M.; Sujka, I.; Volk, B.; Weng, Q.; Wilkes, R. 1, 3-disubstituted-imidazo[1, 5-a]pyrazines as insulin-like growth factor-I receptor (IGF-1R) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(4), 1091-1097.
216. Luan, X.; Gao, C.; Zhang, N.; Chen, Y.; Sun, Q.; Tan, C.; Liu, H.; Jin, Y.; Jiang, Y. Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors. Bioorg. Med. Chem., 2011, 19(11), 3312-3319.
217. Cui, J.J.; Tran-Dubè, M.; Shen, H.; Nambu, M.; Kung, P.P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R.S.; Edwards, M.P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epitelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem., 2011, 54(18), 6342-6363.
218. Development of the first generation c-Met kinase inhibitors: beginning of a path to a new treatment of cancer. Wang, X.; McMahon, G.; Lipson, K.E. Mol. Cancer Ther., 2011, 10(11), 2022.
219. Das, J.; Barrish, J.C. Dasatinib, a kinase inhibitor to treat chronic myelogenous leukemia. In: Analogue-based drug discovery II; Fisher, G.; Ganellin, C.R., Eds.; Wiley-VCH, Weinheim, 2010, pp. 493-506.
220. Boschelli, D.H.; Boschelli, F.; Wu, B.; Ye, F.; Wang, Y.; Golas, J.M.; Young, T.; Lucas, J. SKI-606 and beyond. Hematological Reports, 2005, 1, 28-31.
221. Willhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Disc., 2006, 5(10), 835-844.
222. Wan, P.T.C.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R; Cancer Genome Project. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell, 2004, 116(6), 855-867.
223. Howard, S.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Curry, J.; Devine, L.A.; Early, T.R.; Fazal, L.; Gill, A.L.; Heathcote, M.; Maman, S.; Matthews, J.E.; McMenamin, R.L.; Navarro, E.F.; O'Brien, M.A.; O'Reilly, M.; Rees, D.C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P.G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J. Med. Chem., 2009, 52(2), 379-388.
224. Wyatt, P.G.; Woodhead, A.J.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Davis, D.J.; Devine, L.A.; Early, T.R.; Feltell, R.E.; Lewis, E.J.; McMenamin, R.L.; Navarro, E.F.; O'Brien, M.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L.C.A.; Smith, D.M.; Squires, M.S.; Trewartha, G.; Walker, M.T.; Woolford, A.J.A. Identification of N-(4-piperidinyl)-4-(2, 6- dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem., 2008, 51(16), 4986-4999.
225. Fancelli, D.; Berta, D.; Bindi, S.; Cameron, A.; Cappella, P.; Carpinelli, P.; Catana, C.; Forte, B.; Giordano, P.; Giorgini, M.L.; Mantegani, S.; Marsiglio, A.; Meroni, M.; Moll, J.; Pittala, V.; Roletto, F.; Severino, D.; Soncini, C; Storici, P.; Tonani, R.; Varasi, M.; Vulpetti, A.; Vianello, P. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem., 2005, 48(8), 3080-3084.
226. Fancelli, D.; Moll, J.; Varasi, M.; Bravo, R.; Artico, R; Berta, D.; Bindi, S.; Cameron, A.; Candiani, I.; Cappella, P.; Carpinelli, P.; Croci, W.; Forte, B.; Giorgini, M.L.; Klapwijk, J.; Marsiglio, A.; Pesenti, E.; Rocchetti, M.; Roletto, F.; Severino, D.; Soncini, C; Storici, P.; Tonani, R.; Zugnoni, P.; Vianello, P. 1, 4, 5, 6-tetrahydropyrrolo[3, 4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibitor profile. J. Med. Chem., 2006, 49(24), 7247-7251.
227. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110a inhibitors. Bioorg. Med. Chem., 2006, 14(20), 6847-6858.
228. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.; Friedman, L.S.; Hayes, A.; Hancox, T.C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A.G.; Pang, J.; Patel, S.; Pergl-Wilson, G.H.; Raynaud, F.I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M.H.; Valenti, M.; Wallweber, H.J.A.; Wan, N.C.; Wiesmann, C; Workman, P.; Zhyvoloup, A.; Zvelebil, M.J.; Shuttleworth, S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51(18), 5522-5532.
229. Sutherlin, D.P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W.W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V; Wan, N.C.; Wang, S.; Wiesmann, C; Wong, S.; Zhu, B.Y. Discovery of (thienopyrimidin-2-yl) aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J. Med. Chem., 2010, 53(3), 1086-1097.
230. Wallin, J.J.; Kyle, A.; Edgar, K.A.; Guan, J.; Berry, M.; Prior, W.W.; Lee, L.; Lesnick, J.D.; Lewis, C; Nonomiya, J.; Pang, J.; Salphati, L.; Olivero, A.G.; Sutherlin, D.P.; O'Brien, C; Spoerke, J.M.; Patel, S.; Lensun, L.; Kassees, R; Ross, L.; Lackner, M.R; Sampath, D.; Belvin, M.; and Friedman, L.S.GDC-0980 is a novel Class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther., 2011, 10(12), 2426-2436.
231. Dehnhardt, CM.; Venkatesan, A.M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-kaloustian, S.; Brooijmans, N.; Mallon, R; Hollander, I.; Feldberg, L.; Lucas, J.; Chaudhary, I.; Yu, K.; Gibbons, J.; Abraham, R; Mansour, T.S. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide-3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem., 2010, 53(2), 798-810.
232. Venkatesan, A.M.; Dehnhardt, CM.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R.T.; Chaudhary, I.; Mansour, T.S. Bis(morpholino-1, 3, 5-triazine) derivatives: potent adenosine 5 '-triphosphate competitive phosphatidy linositol-3-kinase/mammalian target of rapamicyn inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem., 2010, 53(6), 2636-2645.
233. Knight, S.D.; Adams, N.D.; Burgess, J.L.; Chaudhari, A.M.; Darcy, M.G.; Donatelli, CA.; Luengo, J.I.; Newlander, K.A.; Parrish, CA.; Ridgers, L.H.; Sarpong, M.A.; Schmidt, S.J.; Van Aller, G.S.; Carson, J.D.; Diamond, M.A.; Elkins, P.A.; Gardiner, CM.; Garver, E.; Gilbert, S.A.; Gontarek, RR; Jackson, J.R; Kershner, K.L.; Luo, L.; Raha, K.; Sherk, CS.; Sung, CM.; Sutton, D.; Tummino, P.J.; Wegrzyn, R.J.; Auger, K.R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett., 2010, 1(1), 39-43.
234. Auger, K.; Luo, L.; Knight, S.D.; Van Aller, G.; Tummino, P.J.; Copeland, RA.; Diamond, M.; Sutton, D.; Lu, H.; Oleykowski, K; Sudakin, V; Dhanak, D.; Jackson, J.R. GSK1059615: a novel inhibitor of phosphoinositide-3-kinase for the treatment of cancer. Proceedings of the 20 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer. Geneva Palexpo, Geneva, Switzerland, 21-24 October 2008.
235. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R; Knigton, D.R; Marx, M.A.; Ninkovic, S.; Sun, S.; Zhang, E. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. MedChemCommun., 2010, 1(2), 139-144.
236. Maira, S.M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C; Fritsch, C; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7(7), 1851-1863.
237. Stauffer, F.; Maira, S.M.; Furet, P.; Garcia-Echeverria, C.G. Imnidazo[4, 5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett., 2008, 18(3), 1027-1030.
238. Nishimura, N.; Siegmund, A.; Liu, L.; Yang, K.; Bryan, M.C.; Andrews, K.L.; Bo, Y.; Booker, S.K.; Caenepeel, S.; Freeman, D.; Liao, H.; McCarter, J.; Mullady, E.L.; San Miguel, T.; Subramanian, R.; Tamayo, N.; Wang, L.; Whittington, D.A.; Zalameda, L.; Zhang, N.; Hughes, P.E.; Norman, M.H. Phosphoinositide-3-kinase (PI3K)/mammalian target of rapamicyn (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. J. Med. Chem., 2011, 54(13), 4735-4751.
239. D'Angelo, N.D.; Kim, T.S.; Andrews, K.; Booker, S.K.; Canepeel, S.; Chen, K.; D'Amico, D.; Freeman, D.; Jiang, J.; Liu, L.; McCarter, J.D.; San Miguel, T.; Mullady, E.L.; Schrag, M.; Subramanian, R.; Tang, J.; Wahl, R.C.; Wang, L.; Whittington, D.A.; Wu, T.; Xi, N.; Xu, Y.M.; Yakowec, P.; Yang, K; Zalameda, L.P.; Zhang, N.; Hughes, P.; Norman, M.H. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamicyn (mTOR) dual inhibitors. J. Med. Chem., 2011, 54(6), 1789-1811.
240. Stec, M.M.; Andrews, K.; Booker, S.K.; Canepeel, S.; Freeman, D.J.; Jiang, J.; Liao, H.; McCarter, J.; Mullady, E.L.; San Miguel, T.; Subramanian, R.; Tamayo, N.; Wang, L.; Yang, K.; Zalameda, L.P.; Zhang, N.; Hughes, P.E.; Norman, M.H. Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6, 5-heterocycles to improve metabolic stability. J. Med. Chem., 2011, 54(14), 5174-5184.
241. Apsel, B.; Blair, J.A.; Gonzalez, B.; Nazif, T.M.; Feldman, M.E.; Aizenstein, B.; Hoffman, R.; Williams, R.L.; Shokat, K.M.; Knight, Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinisitide kinases. Nat. Chem. Biol., 2011, 4(10), 691-699.
242. William, A.D.; Lee, A.C.H.; Blanchard, S.; Poulsen, A.; Teo, E.L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E.T.; Goh, K.C.; Ong, W.C.; Goh, S.K.; Hart, S.; Jayaraman, R.; Khalid Pasha, M.; Ethirajulu, K.; Wood, J.M.; Dymock, B.W. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-triaza tetracyclo[19.3.1.1[2, 6).1(8, 12)]heptacosa1(25), 2(26), 3, 5, 8, 10, 12(27), 16, 21, 23-decaene(SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inibitor for the treatment of myelofibrosis and lymphoma. J. Med. Chem., 2011, 54(13), 4638-4658.
243. William, A.D.; Lee, A.C.H.; Goh, K.C.; Blanchard, S.; Poulsen, A.; Teo, E.L.; Nagaraj, H.; Lee, C.P.; Wang, H.; Williams, M.; Sun, E.T.; Hu, C.; Jayaraman, R.; Khalid Pasha, M.; Ethirajulu, K.; Wood, J.M.; Dymock, B.W. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5, 7, 14, 26-tetraazatetracyclo[19.3.1.1(2, 6).1(8, 12)]heptacosa-1(25), 2(26), 3, 5, 8(27), 9, 11, 16, 21, 23-decaene (SB-1317/TG02), a potent inhibitor of cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine kinase-3 (FLT3) for the treatment of cancer. J. Med. Chem., 2012, 55(1), 169-196.
244. Smyth, L.A.; Collins, I. Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol., 2009, 2(3), 131-151.
245. Ryckmans, T.; Edwards, M.P.; Hornea, V.A.; Correiac, A.M.; Owena, D.R.; Thompsona, L.R.; Trana, I.; Tuttc, M.F.; Youngs, T. Rapid assessment of a new series of selective CB2 agonists using parallel synthesis protocols: a lipophylic efficiency (LipE) analysis. Bioorg. Med. Chem. Lett., 2009, 19(15), 4406-4409.
246. Edwards, M.P.; Price, D.A. Role of physicochemical properties and lipophilic ligand efficiency (LipE or LLE) in addressing drug safety risks. Annu. Rep. Med. Chem., 2010, 45, 381-391.
247. Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Disc., 2007, 6(11), 881.
248. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Disc. Today, 2004, 9(10), 430-431.
249. Abad-Zapatero, C.; Metz, J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Disc. Today, 2005, 10(7), 464-467.
250. Coumar, M.; Tsai, M.T.; Chu, C.Y.; Uang, B.J.; Lin, W.H.; Chang, C.Y.; Chang, T.Y.; Leou, J.S.; Teng, C.H.; Wu, J.S.; Fang, M.Y.; Chen, C.H.; Hsu, J.T.A.; Wu, S.Y.; Chao, Y.S.; Hsieh, H.P. Identification, SAR studies, and X-ray co-crystallographic analisys of a novel furanoprimidine Aurora Kinase A inhibitor. ChemMedChem, 2010, 5(2), 255-267.
251. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9(1), 28-39.
252. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4(11), 682-690.
253. Aronov, A.M.; McClain, B.; Moody, C.S.; Murcko, M.A. Kinase likeness and kinase-privileged fragments: toward virtual polypharmacology. J. Med. Chem., 2008, 51(5), 1214-1222.
254. Metz, J.T.; Johnson, E.F.; Soni, N.B.; Merta, P.J.; Kifle, L.; Hajduk, P.J. Navigating the kinome Nature Chem Biol., 2011, 7(4), 200-202.
255. Vulpetti, A.; Bosotti, R. Sequence and structural analysis of kinase AT P pocket residues. Farmaco, 2004, 59(10), 759-766.
256. Fancelli, D.; Moll, J. Discovery of PHA-739358. In: Kinase inhibitor drugs; Li, R.; Stafford, J.A., Eds.; Wiley, Hoboken, New Jersey, 2009, pp. 281-307.
257. Drewry, D.H.; Bambourgh, P.; Schneider, K.; Smith, G.K. The kinome and its impact on medicinal chemistry. In: Kinase Drug Discovery; Ward, R.A.; Goldberg, F. Eds.; Royal Society of Chemistry, Cambridge, 2012, pp. 1-29.
258. Furet, P.; Bold, G.; Hofmann, F.; Manley, P.; Meyer, T.; Altmann, H.K. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg. Med. Chem. Lett. 2003, 13(18), 2967-2971.
259. Liechti, C; Sequin, U.; Bold, G.; Furet, P.; Meyer, T.; Traxler, P. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor. Eur. J. Med. Chem., 2004, 39(11), 11-26.
260. Furet, P.; Caravatti, G; Guagnano, V.; Lang, M.; Meyer, T.; Schoepfer, J. Entry into a new class of protein kinase inhibitors by pseudo ring design. Bioorg. Med. Chem. Lett., 2008, 18(3), 897-900.
261. Liu, K.K.C.; Huang, X.; Bagrodia, S.; Chen, J.H.; Greasley, S.; Cheng, H.; Sun, S.; Knighton, D.; Rodgers, C; Rafidi, K.; Zou, A.; Xiao, J.; Yan, S. Quinazolines with intra-molecular hydrogen-bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(4), 1270-1274.
262. Guagnano, V.; Furet, P.; Spanka, C; Bordas, V.; Le Douget, M.; Stamm, C; Brueggen, J.; Jensen, M.R.; Schnell, C; Schmidt, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Porta, D.G. Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-[6-[4-(4-ethyl-piperazin-1-yl)- phenylamino]-pyrimidin-4-yl]1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the Fibroblast Growth Factor Receptor family of receptor tyrosine kinase. J. Med. Chem., 2011, 54(20), 7066-7083.
263. Mortlock, A.; Keen, N. J.; Jung, F. H.; Heron, N. M.; Foote, K. M.; Wilkinson, R; Green, S. Progress in the Development of Selective Inhibitors of Aurora Kinases. Curr. Top. Med. Chem., 2005, 5(2), 199-213.
264. Warner, S. L.; Bashyam, S.; Vankayalapati, H.; Bearss, D. J.; Han, H.; Von Hoff, D. D.; Hurley, L. H. Identification of a Lead Small-Molecule Inhibitor of the Aurora Kinases Using a Structure-Assisted, Fragment-Based Approach. Mol. Cancer Ther, 2006, 5(7), 1764-1773.
265. Cancilla, M. T.; He, M. M.; Viswanathan, N.; Simmons, R L.; Taylor, M.; Fung, A. D.; Cao, K.; Erlanson, D. A. Discovery of an Aurora Kinase Inhibitor through Site-Specific Dynamic Combinatorial Chemistry. Bioorg. Med. Chem. Lett., 2008, 18(14), 3978-3981.
266. Oyarzabal, J.; Zarich, N.; Albarran, M.I.; Palacios, I.; Urbano-Cuadrado, M.; Mateos, G.; Reymundo, I.; Rabal, O.; Salgado, A.; Corrionero, A.; Fominaya, J.; Pastor, J.; Bischoff, J.R Discovery of mitogen-activated protein kinase-interactiong kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. J. Med. Chem., 2010, 53(18), 6618-6628.
267. Vieth, M.; Erickson, J.; Wang, J.; Webster, Y.; Mader, M.; Higgs, R.; Watson, I. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. J. Med. Chem., 2009, 52(20), 6456-6466.
268. Aronov, A.M.; McClain, B.; Moody, C.S.; Murcko, M.A. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. J. Med. Chem., 2008, 51(5), 1214-1222.
269. Bamborough, P.; Brown, M.J.; Christopher, J.A.; Chung, C; Mellor, G.W. Selectivity of kinase inhibitor fragments. J. Med. Chem., 2011, 54(14), 5131-5143.
270. Cai, X.; Zhai, H.X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.J.; Bao, R; Qian, C. Discovery of 7-(4-(3-ethynyl phenylamino)-7-methoxyquinazolin- 6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53(5), 2000-2009.
271. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of a chimeric histone deacetylase-and tyrosine kinase-inhibitors: a series of Imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rß, and histone deacetylases. J. Med. Chem., 2009, 52(8), 2265-2279.
272. Chen, L.; Petrelli, R; Gao, G.; Wilson, D.J.; McLean, G.T.; Jayaram, H.N.; Sham, YY; Pankiwicz, K.W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg. Med. Chem., 2010, 18(16), 5950-5964.
273. Guerrant, W.; Patil, V.; Canzoneri, J.C.; Oyelere, A.K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem., 2012, 55(4), 1465-1477.
274. Cai, X.; Zhai, H.X.; Lai, C.J.; Bao, R.; Gould, S.; Qian, C. Design and synthesis of quinazoline derivatives as novel, potent multi-acting HDAC and Receptor Tyrosine kinase inhibitors for the treatment of cancer. 235th National meeting of ACS, April 6-10, New Orleans, 2008.
275. Curis (a drug development company) Web page: www.curis.com (Accessed February 14, 2012).
276. Woo, L.W.L.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K.R; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V.L. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J. Med. Chem., 2010, 53(5), 2155-2170.
277. Rajasethupathy, P.: Vayttaden, S.J.; Bhalla, U.S. Systems modeling: a pathway to drug discovery. Curr. Opin. Chem. Biol., 2005, 9(4), 400-406.
278. Butcher, E.C. Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov, 2005, 4(6), 461-467.
279. van der Greef, J.; McBurney, R.N. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov., 2005, 4(12), 961-967.
280. Pasquier, E.; Kavallaris, M.; Andri, N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol., 2010, 7(8), 455-465.
281. Andre, N.; Pasquier, m E. For cancer, seek and destroy or live and let live? Nature, 2009, 460(7253), 324.
282. Palmberg, E.; Johnsen, J.I.; Paulsson J. et al., Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int. J. Cancer, 2009, 124(5), 1227-1234.
283. Vander Heiden, M.G. Targeting cancer metabolism: a therapeutic window open. Nat. Rev. Drug Disc., 2011, 10(8), 671-684.
284. Shlomi, T.; Benyamini, T.; Gottlieb, E.; Sharan, R.; Ruppin, E. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Computat. Biol., 2011, 7, e1002018.
285. Folger, O.; Jerby, L.; Frezza, C.; Gottlieb, E.; Ruppin, E.; Shlomi, T. Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol., 2011, 7, 501.
286. Perumal, D.; Samal, A.; Sakharkar, K.R.; Sakharkar, M.K. Targeting multiple targets in Pseudomonas aeruginosa PAO1 using flux balance analysis of a reconstituted genome-scale metabolic network. J. Drug Targ., 2011, 19(1), 1-13.
287. Strong, M.; Eisenberg, D. The protein network as a tool for finding novel drug targets. In: Progress in Drug Research; Bushoff, H.I.; Barry, C.E. Eds.; Birkhauser, Basel, 2007, 64, pp. 192-215.
288. Ozbayraktar, F.B.K.; Ulgen, K.O. Drug target identification is sphingolipid metabolism by computational system biology tools: metabolic control analysis and metabolic pathway analysis. J. Biomed. Inf., 2010, 43(4), 537-549.
289. Moreno-Sanchez, R.; Saavedra, E.; Rodriguez-Enriquez, S.; Gallardo-Perez, J.C.; Quezada, H.; Westerhoff, H.V. Metabolic control analysis indicates a change of strategy in the treatment of cancer. Mitochondrion, 2010, 10(6), 626-639.
290. Cheong, J.H.; Park, E.S.; Liang, J.; Dennison, J.B.; Tsavachidou, D.; Nguyen-Charles, C.; Cheng, K.W.; Hall, H.; Zhang, D.; Lu, Y.; Ravoori. M.; Kundra, V.; Ajani, J.; Lee, J.S.; Hong, W.K.; Mills, G.B. Dual inhibition of tumor energy pathway by 2-deoxy glucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther., 2011, 10(12), 2350-2362.
291. Lotsch, Q.J.; Geisslinger, G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Disc. Today, 2011, 16(23-24), 1001-1006.
292. Yang, K.; Ma, W.; Liang, H.; Ouyang, Q.; Tang, C.; Lai, L. Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput. Biol., 2007, 3(3): e55.doi:10.1371/journal.pcbi.0030055.
293. Wei, D.; Jiang, X.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J.; Lai, L. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem., 2008, 51(24), 7882-7888.
294. Chen, Z.; Wu, Y.; Liu, Y.; Yang, S.; Chen, Y.; Lai, L. Discovery of dual target inhibitors against cyclooxigenases and leukotriene A4 hydrolase. J. Med. Chem., 2011, 54(10), 3650-3660.
295. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthetase-1 and 5-lipoxigenase. J. Med. Chem., 2008, 51(24), 8068-8076.
296. Hieke, M.; Greiner, C.; Dittrich, M.; Reisen, F.; Schneider, G.; Shubert-Zsilavecz, M.; Werz, O. Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4, 6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid. J. Med. Chem., 2011, 54(13), 4490-4507.
297. Drugdevelopment technology.com (a site dealing with news, views and contacts from the global drugdevelopment industry) Web page: www.drugdevelopment-technology.com/projects/licofelone/(Accessed February 14, 2012).
298. Laufer, S.A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6, 7-diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem., 1994, 37(12), 1894-1897.
299. Vidal, C.; Gomez-Hernandez, A.; Sanchez-Galan, E.; Gonzalez, A.; Ortega, L.; Gomez-Gerique, J.A.; Tunon, J.; Egido, J. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J. Pharmacol. Exp. Ther., 2007, 320(1), 108-116.
300. Liu, J.; Fu, Z.; Wang, Y.; Schmitt, M.; Huang, A.; Marshall, D.; Tonn, G.; Seitz, L.; Sullivan, T.; Tang, H.L.; Collins, T.; Medina, J. Discovery and optimization of CRTH2 and DP dual antagonists. Bioorg. Med. Chem. Lett., 2009, 19(22), 6419-6423.
301. Merlos, M.; Giral, M.; Balsa, D.; Ferrando, R.; Queralt, M.; Puidgemont, A.; Garcia-Rafanell, J.; Forn, J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther., 1997, 280(1), 114-121.
302. Carceller, E.; Merlos, M.; Giral, M.; Balsa, D.; Almansa, C.; Bartroli, J.; Garcia-Rafanell, J.; Forn, J. [(3-pyridylalkyl)piperidylidene]benzocyclo- heptapyridine derivatives as dual antagonists of PAF and histamine. J. Med. Chem., 1994, 37(17), 2697-2703.
303. Piwinski, J.J.; Jesse, K.W.; Green, M.J.; Ganguly, A.K.; Billah, M.M.; West, R.E.; Kreutner, W. Dual antagonists of Platelet Activating Factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5, 6-dihydro-11H-benzo[5, 6]-cyclohepta-[1, 2-b]pyridine-11-ylidene) piperidines. J. Med. Chem., 1991, 34(1), 457-461.
304. th 2009 at the national heart and lung institute, London, UK. Drugs. Fut. 2010, 35(4), 349-358.
305. Zhi, C.; Long, Z.; Manikowski, A.; Comstock, J.; Xu, W.C.; Brown, N.C.; Tarantino, P.M.; Holm, K.A.; Dix, E.J.; Wright, G.E.; Barnes, M.H.; Butler, M.M.; Foster, K.A.; LaMarr, W.A.; Bachand, B.; Bethell, R.; Cadilhac, C.; Charron, S.; Lamothe, S.; Motorina, I.; Storer, R. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J. Med. Chem., 2006, 49(4), 1455-1465.
306. Ziebart, K.T.; Dixon, S.M.; Avila, B.; El-Badri, M.H.; Guggenheim, K.G.; Kurth, M.J.; Toney, M.D. Targeting multiple chorismate-utilizing enzymes with a single inhibitor: validation of a three-stage design. J. Med. Chem., 2010, 53(9), 3718-3729.
307. Wang, Z.; Bennett, E.M.; Wilson, D.J.; Salomon, C.; Vince, R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J. Med. Chem., 2007, 50(15), 3416-3419.
308. Charifson, P.S.; Grillot, A.L.; Grossman, T.H.; Parson, J.D.; Badia, M.; Bellon, S.; Deininger, D.D.; Drumm, J.E.; Gross, C.H.; LeTiran, A.; Liao, Y.; Mani, N.; Nicolau, D.P.; Perota, E.; Ronkin, S.; Shannon, D.; Swenson, L.L.; Tang, Q.; Tessier, P.R.; Tian, S.K.; Trudeau, M.; Wang, T.; Wei, Y.; Zhang, H.; Stamos, D. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and tiopoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J. Med. Chem., 2008, 51(17), 5243-5263.
309. Silver, L.L. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Disc., 2007, 6(1), 41-55.
310. Chandra, N.; Kumar, D.; Rao, K. Systems biology of tubercolosis. Tuberculosis, 2011, 91, S1, 487-496.
311. Cavalli, A.; Muregi, F.W.; Ishih, A. Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design. Drug Dev. Res., 2010, 71(1), 20-32
312. Cosledan, F.; Fraisse, L.; Pellet, A.; Guillou, F.; Mordmuller, B.; Kremsner, P.G.; Moreno, A.; Mazier, D.; Maffrand, J.P.; Meunier, B. Selection of a trioxaquine as an antimalarial drug candidate. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(45), 17579-17584.
313. Hornberg, J.J.; Bruggerman, F.J.; Bakker, B.M.; Westerhoff, H.V. Metabolic control analysis to identify optimal drug targets. In: Progress in Drug Research; Bushoff, H.I.; Barry, C.E. Eds.; Birkhauser, Basel, 2007, 64, pp. 172-189.
314. Roth, B.L.; Sheffler, D.J.; Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Disc., 2004, 3(4), 353-359.
315. Arnt, J.; Bang-Andersen, B.; Dias, R.; Bogeso, K.P. Strategies for pharmacotherapy of schizophrenia. Drugs Fut., 2008, 33(9), 777-791.
316. Essock, S.M.; Schooler, R.N.; Stroup, T.S.; McEvoy, J.P.; Rojas, I.; Jackson, C.; Covell, N.H. Schizophrenia trials network: effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry, 2011, 168(7), 702-708.
317. Correll, C.U.; Rummel-Kluge, C.; Corves, C.; Kane, J.M.; Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analisys of randomized controlled trials. Schizophr. Bull., 2009, 35(2), 443-457.
318. Malhi, G.S.; Berk, M. dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust. N. Z. J. Psychiatry, 2008, 42(4), 346-349.
319. Ross, C.A.; Margolis, R.L.; Reading, S.A.; Pletnikov, M.; Coyle, J.T. Neurobiology of schizophrenia. Neuron, 2006, 52(1), 139-153.
320. Bianchi, M.T.; Pathmanathan, J.; Cash, S.S. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med. Hypothesis, 2009, 72(3), 297-305.
321. Hase, T.; Tanaka, H.; Suzuki, Y.; Nakagawa, S.; Kitano, H. Structure of protein interaction networks and their implicationson drug design. PLoS Comput. Biol., 2009, 5, e1000550.
322. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Disc., 2002, 1(7), 493-502.
323. Fabian, M.A.; Biggs, W.H.; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lelias, J.M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockart, D.J. A small-molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol., 2005, 23(3), 329-336.
324. Daub, H. Kinase inhibitors: narrowing down the real target. Nat. Chem. Biol., 2010, 6(4), 249-50.
325. Woodcock, J.; Griffin, J.P.; Behrman, R.E. Development of novel combination therapies. N. Eng. J. Med., 2011, 364, 985-987.
326. Podolsky, S.H.; Greene, J.A. Combination drugs-hype, harm, and hope. New Eng. J. Med., 2011, 365, 488-491.
327. Bangalore, S.; Kamalakkannan, G.; Parkar, S.; Messerli, F.H. Fixed-dose combinations improve medication compliance: a meta-analisys. Am. J. Med., 2007, 120(8), 713-719.
328. Schoeberl, B.; Pace, E.A.; Fitzgerald, J.B.; Harms, B.D.; Xu, L.; Nie, L.; Linggi, B.; Kalra, A.; Paragas, V.; Bukhalid, R.; Grantcharova, V.; Kohli, N.; West, K.A.; Leszczyniecka, M.; Feldhaus, M.J.; Kudla, A.J.; Nielsen, U.B. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal., 2009, 2, 77, ra31.
329. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci., 2005, 26(4), 178-182.
330. e-Therapeutics plc (the Network Pharmacology Company) Web page: www.e-therapeutics.co.uk/Drug-Discovery/drug-discovery.html (Accessed February 14, 2012).
331. Young, M.P.; Yates, C.M.; Idowu, O.C.; Charlton, J.A. Treatment of depression. WO2009001040, 2008.
332. Young, M.P.; McKeown, P. Dexanabinol and derivatives thereof for inducing cancer cell apoptosis. WO2011030106, 2011.